DBV Technologies S.A. DBVT
9.94 USD -0.17 (-1.68%)
At closeNov 5, 2026, 8:04 AM EST
10.12 +0.18 +1.81%
Pre-market · Nov 5, 8:04 AM ET
9.76 Day range 10.41
8.63 52-week range 26.19
- YTD
- -48.15%
- 1 year
- -30.78%
News
globenewswire.com DBV Technologies to Participate in Upcoming November Investor Conferences Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the…
benzinga.com Guggenheim Maintains Buy on DBV Technologies, Lowers Price Target to $46 Guggenheim analyst Yatin Suneja maintains DBV Technologies (NASDAQ:DBVT) with a Buy and lowers the price target from $51 to $46.
benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Lowers Price Target to $47 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and lowers the price target from $55 to $47.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com ServiceNow Posts Downbeat Q3 Earnings, Joins Sprouts Farmers Market, Alphabet And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as ServiceNow plunged 18.5% after missing earnings estimates, while Fortinet, Sprouts and Alphabet also fell.
seekingalpha.com DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript
marketbeat.com What DBV Technologies (DBVT) Said on Its Q3 Earnings Call DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while…
benzinga.com DBV Technologies Q3 2026 Earnings Call Transcript DBV Technologies (NASDAQ:DBVT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com DBV Technologies Q3 EPS $(0.14) Beats $(0.24) Estimate, Sales $1.600M Beat $820.000K Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 41.67 percent increase over losses of…
globenewswire.com DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut…
globenewswire.com DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at…
defenseworld.net Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the…
defenseworld.net DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year Low – What’s Next? DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $8.90 and last traded at $9.03, with a volume…
defenseworld.net DBV Technologies (NASDAQ:DBVT) Sets New 1-Year Low – Time to Sell? Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) hit a new 52-week low on Thursday. The company traded as low as $9.64 and last traded at $9.77, with a volume of 535276 shares…
defenseworld.net DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next? DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $11.76, but opened at $11.30. DBV Technologies shares last…
benzinga.com Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsThe BLA is supported by the results from the successful…
globenewswire.com DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is…
defenseworld.net DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis DBV Technologies (NASDAQ: DBVT - Get Free Report) and XTL Biopharmaceuticals (NASDAQ: XTLB - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
globenewswire.com DBV Technologies to Participate in Upcoming September Investor Conferences Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the…
globenewswire.com Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
globenewswire.com DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN:…
seekingalpha.com DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap DBV Technologies is rated Buy following positive Phase 3 VITESSE results. My risk- and dilution-adjusted DCF yields $42 per ADS, more than double the current share price. The model assumes that 60%…
seekingalpha.com DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT's transition from research to commercial readiness is evident, with rising…
globenewswire.com DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market:…
seekingalpha.com DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
marketbeat.com DBV Technologies Q2 Earnings Call Highlights DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7,…
globenewswire.com DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report Châtillon, France, July 16, 2026 DBV Te c hnologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN:…
benzinga.com DBV Technologies Q2 EPS $(0.12) Misses $(0.10) Estimate, Sales $700.000K Miss $1.391M Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 61.29 percent increase over losses of…- benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $47 to $55.
benzinga.com DBV Technologies To Present New Data From VITESSE Study And Preview Recently Initiated THRIVE Study At EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic…
benzinga.com DBV Technologies Starts Infant Study of Peanut Allergy Patch DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and…
benzinga.com Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $51 price target.
benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $47 to $55.- benzinga.com DBV Technologies Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $900.000K Miss $1.268M Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 57.69 percent increase over losses of…
benzinga.com DBV Technologies Sets Stage For 'Swift' Success As Breakthrough Peanut Patch Nears FDA Submission DBV Tech (DBVT) maintains progress with BLA submission for VIASKIN peanut patch in children. Analyst maintains Buy rating with $51 target.
benzinga.com Alphabet To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, visit our analyst ratings page.- benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $47 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $45 to $47.
- benzinga.com Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $51 price target.
- benzinga.com DBV Technologies Q4 EPS $(0.23) Beats $(0.63) Estimate, Sales $645.000K Miss $655.000K Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.63) by 63.49 percent. This is a 4.55 percent decrease over losses of…
benzinga.com Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings and sales. Other stocks also down in pre-market.
benzinga.com Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings and sales. Other stocks also down in pre-market.- benzinga.com Reported Saturday, DBV Technologies Reports Broad Desensitization In Phase 3 VITESSE Study, 60.1% Increase Two Doses With VIASKIN Peanut Patch Vs 23.4% Placebo DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual MeetingApproximately 83% of children treated with the VIASKIN® Peanut Patch increased their…
- benzinga.com DBV Technologies To Present VITESSE Phase 3 Study Of VIASKIN Peanut Patch Data At AAAAI 2026 Annual Meeting DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday 
benzinga.com How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.
benzinga.com Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session